NICE clears Xolair for hives
This article was originally published in Scrip
Executive Summary
NICE has recommended Novartis's Xolair (omalizumab) as an option for treating severe chronic spontaneous urticaria (also known as hives) in some adults and young people aged 12 years and over. It has been is recommended on the basis that it will be provided to the NHS at a reduced price as part of the patient access scheme. Xolair was approved and cleared by NICE for allergic asthma but almost had that recommendation rescinded in 2012 but Novartis managed to persuade NICE to uphold the original decision after putting a patient access scheme in place. However, when Xolair initially came before NICE for the hives indication, Novartis was asked to provide more details and analysis on the submission. In March, NICE indicated in final draft guidance that it was satisfied with Novartis's efforts.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.